Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LYD001
MIFTS: 47

Leydig Cell Tumor

Categories: Cancer diseases, Reproductive diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Leydig Cell Tumor

About this section

MalaCards integrated aliases for Leydig Cell Tumor:

Name: Leydig Cell Tumor 12 55 44 15 73
Leydig Cell Tumor, Benign 73
Leydig Cell Neoplasm 12
Tumor, Leydig Cell 40

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2696
MeSH 44 D007984
NCIt 50 C3188
SNOMED-CT 68 189739005 45002009
Sources

Summaries for Leydig Cell Tumor

About this section
MalaCards based summary : Leydig Cell Tumor, also known as leydig cell tumor, benign, is related to testicular leydig cell tumor and hyperandrogenism. An important gene associated with Leydig Cell Tumor is LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor), and among its related pathways/superpathways are DAG and IP3 signaling and Aldosterone synthesis and secretion. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include testis, ovary and endothelial, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Sources

Related Diseases for Leydig Cell Tumor

About this section

Diseases in the Leydig Cell Tumor family:

Malignant Leydig Cell Tumor

Diseases related to Leydig Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Related Disease Score Top Affiliating Genes
1 testicular leydig cell tumor 31.7 CYP11A1 CYP17A1 CYP21A2 STAR
2 hyperandrogenism 30.2 CYP17A1 CYP19A1 CYP21A2
3 precocious puberty 30.2 CYP19A1 CYP21A2 LHCGR
4 adrenal rest tumor 29.9 CYP21A2 NR5A1
5 sex cord-gonadal stromal tumor 29.5 AFP NR5A1
6 cryptorchidism, unilateral or bilateral 29.4 CYP19A1 INSL3 NR5A1
7 amenorrhea 29.4 LHCGR NR5A1
8 pseudohermaphroditism 29.0 CYP17A1 CYP19A1 LHCGR NR5A1
9 infertility 28.9 CYP19A1 INSL3 LHCGR NR5A1
10 adrenal adenoma 28.9 CYP11A1 CYP17A1 CYP21A2
11 lipoid congenital adrenal hyperplasia 26.9 CYP11A1 CYP17A1 CYP19A1 CYP21A2 NR5A1 STAR
12 sertoli-leydig cell tumor 12.6
13 goiter, multinodular 1, with or without sertoli-leydig cell tumors 12.5
14 malignant leydig cell tumor 12.3
15 malignant sertoli-leydig cell tumor of the ovary 12.3
16 malignant testicular leydig cell tumor 12.1
17 malignant sertoli-leydig cell tumor 12.1
18 penis agenesis 10.6 CYP17A1 LHCGR
19 testotoxicosis 10.6 CYP19A1 LHCGR
20 precocious puberty, male-limited 10.5 CYP19A1 LHCGR
21 estrogen excess 10.5 CYP19A1 LHCGR
22 mammographic density 10.4 CYP17A1 CYP19A1
23 cytochrome p450 oxidoreductase deficiency 10.4 CYP17A1 CYP21A2
24 mycetoma 10.4 CYP17A1 CYP19A1
25 anorchia 10.3 INSL3 NR5A1
26 sclerosing hepatic carcinoma 10.3 AFP PTHLH
27 alopecia, androgenetic, 1 10.3 CYP19A1 CYP21A2
28 liver sarcoma 10.3 AFP PTHLH
29 gynecomastia 10.2
30 chorioangioma 10.2 AFP PTHLH
31 hemangioma of intra-abdominal structure 10.2 AFP PTHLH
32 uterine anomalies 10.1 AFP CYP19A1
33 dysgerminoma of ovary 10.1 AFP PTHLH
34 androgen insensitivity syndrome 10.1
35 cloacal exstrophy 10.1 AFP NR5A1
36 rhabdomyosarcoma 10.1
37 complete androgen insensitivity syndrome 10.1
38 transsexualism 10.0 CYP17A1 CYP19A1 CYP21A2
39 multinodular goiter 10.0
40 sarcoma 10.0
41 goiter 10.0
42 antley-bixler syndrome 10.0 CYP17A1 CYP19A1 CYP21A2
43 aging 10.0
44 cervicitis 10.0
45 cystadenoma 10.0
46 adenocarcinoma 10.0
47 teratoma 10.0
48 47, xxy 10.0
49 stuttering 10.0 CYP17A1 CYP19A1
50 reproductive system disease 9.9 CYP19A1 LHCGR NR5A1

Graphical network of the top 20 diseases related to Leydig Cell Tumor:



Diseases related to Leydig Cell Tumor
Sources

Symptoms & Phenotypes for Leydig Cell Tumor

About this section

GenomeRNAi Phenotypes related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.36 CYP21A2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.36 CYP21A2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.36 NR5A1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.36 NR5A1 CYP11A1 CYP21A2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.36 CYP21A2 CYP11A1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.36 CYP21A2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.36 CYP21A2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.36 CYP11A1

MGI Mouse Phenotypes related to Leydig Cell Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 PTHLH CYP17A1 CYP19A1 INSL3 LHCGR AFP
2 cellular MP:0005384 9.87 CYP11A1 PTHLH CYP17A1 CYP19A1 INSL3 LHCGR
3 endocrine/exocrine gland MP:0005379 9.86 PTHLH STAR CYP19A1 INSL3 LHCGR AFP
4 growth/size/body region MP:0005378 9.7 NR5A1 CYP11A1 PTHLH CYP17A1 STAR CYP19A1
5 homeostasis/metabolism MP:0005376 9.56 CYP11A1 PTHLH CYP17A1 STAR CYP19A1 LHCGR
6 reproductive system MP:0005389 9.28 PTHLH CYP17A1 STAR CYP19A1 INSL3 LHCGR
Sources

Drugs & Therapeutics for Leydig Cell Tumor

About this section

Drugs for Leydig Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
2
Testosterone Approved, Investigational Phase 2, Phase 3 58-22-0 6013
3
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0
5
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4
6 Anabolic Agents Phase 2, Phase 3
7 Androgens Phase 2, Phase 3
8 Antineoplastic Agents, Hormonal Phase 2, Phase 3
9 Cathartics Phase 2, Phase 3
10 Gastrointestinal Agents Phase 2, Phase 3
11 Hormone Antagonists Phase 2, Phase 3
12 Hormones Phase 2, Phase 3
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
14 Laxatives Phase 2, Phase 3
15 Testosterone 17 beta-cypionate Phase 2, Phase 3
16 Castor Nutraceutical Phase 2, Phase 3
17
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3
19
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
20
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
21
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
22
Etoposide Approved Phase 2 33419-42-0 36462
23 Albumin-Bound Paclitaxel Phase 2
24 Antimitotic Agents Phase 2
25 Antineoplastic Agents, Phytogenic Phase 2
26 Angiogenesis Inhibitors Phase 2
27 Angiogenesis Modulating Agents Phase 2
28 Antibodies Phase 2
29 Antibodies, Monoclonal Phase 2
30 Endothelial Growth Factors Phase 2
31 Immunoglobulin G Phase 2
32 Immunoglobulins Phase 2
33 Mitogens Phase 2
34 Anti-Bacterial Agents Phase 2
35 Antibiotics, Antitubercular Phase 2
36 Etoposide phosphate Phase 2
37 Topoisomerase Inhibitors Phase 2
38
Gemcitabine Approved Phase 1 95058-81-4 60750
39 Anti-Infective Agents Phase 1
40 Antimetabolites Phase 1
41 Antimetabolites, Antineoplastic Phase 1
42 Antiviral Agents Phase 1
43 Immunosuppressive Agents Phase 1
44
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
45
Dactinomycin Approved, Investigational 50-76-0 2019 457193
46
Doxorubicin Approved, Investigational 23214-92-8 31703
47
Ifosfamide Approved 3778-73-2 3690
48
Vincristine Approved, Investigational 2068-78-2, 57-22-7 5978
49
Doxil Approved June 1999 31703
50
Isophosphamide mustard 0

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Androgen for Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
2 Paclitaxel in Treating Patients With Ovarian Stromal Cancer Completed NCT00006227 Phase 2 Paclitaxel
3 Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
4 Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Recruiting NCT01042522 Phase 2 Carboplatin;Cisplatin;Etoposide Phosphate;Paclitaxel
5 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
6 Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors Completed NCT01572467
7 Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer Completed NCT01764789 Not Applicable
8 DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
9 International PPB Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
10 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Recruiting NCT00565903

Search NIH Clinical Center for Leydig Cell Tumor

Cochrane evidence based reviews: leydig cell tumor

Sources

Genetic Tests for Leydig Cell Tumor

About this section
Sources

Anatomical Context for Leydig Cell Tumor

About this section

MalaCards organs/tissues related to Leydig Cell Tumor:

41
Testis, Ovary, Endothelial, Lung, Testes, Prostate, Pituitary
Sources

Publications for Leydig Cell Tumor

About this section

Articles related to Leydig Cell Tumor:

(show top 50) (show all 396)
# Title Authors Year
1
Retroperitoneal Leydig cell tumor recurrence presenting 14 years after orchiectomy. ( 29524977 )
2018
2
Familial multinodular goiter and Sertoli-Leydig cell tumors associated with a large intragenic in-frame<i>DICER1</i>deletion. ( 29187512 )
2018
3
An ovarian Leydig cell tumor of ultrasound negative in a postmenopausal woman with hirsutism and hyperandrogenism: A case report. ( 29517680 )
2018
4
Poorly differentiated, ovarian Sertoli-Leydig cell tumor with heterologous rhabdomyosarcoma and glandular elements: Diagnosis and management of a rare neoplasm. ( 29922708 )
2018
5
Testicular Estrogen-Secreting Leydig Cell Tumor in 18F-FDG PET/CT: An Incidental Detection in a Patient Treated by Chemotherapy for Hodgkin Lymphoma. ( 29166332 )
2018
6
Management of testicular Leydig cell tumor: A case report. ( 29924022 )
2018
7
Synchronous Leydig Cell Tumor and Seminoma in the Ipsilateral Testis. ( 29670803 )
2018
8
Mitotane treatment in patients with metastatic testicular Leydig cell tumor associated with severe androgen excess. ( 29330226 )
2018
9
A Multicenter Retrospective Review of Pediatric Leydig Cell Tumor of the Testis. ( 29554024 )
2018
10
Case report: an identical twin with Sertoli-Leydig cell tumor. ( 29366348 )
2018
11
Ovarian Sertoli-Leydig Cell Tumor With Heterologous Hepatocytes and a Hepatocellular Carcinomatous Element. ( 29620585 )
2018
12
Ovarian Sertoli-Leydig Cell Tumor with Elevated Inhibin B as a Cause of Secondary Amenorrhea in an Adolescent with Germ Line DICER1 Mutation. ( 28502826 )
2017
13
Leydig cell tumor in ovary of a German Shepherd bitch: An immunohistopathological study. ( 28473902 )
2017
14
Leydig cell tumor in grey zone: A case report. ( 28419904 )
2017
15
Leydig Cell Tumor of Testis in a Child: An Uncommon Presentation. ( 28694581 )
2017
16
Leydig cell tumor in the post-menopausal woman: case report and literature review. ( 28112699 )
2017
17
Retiform Sertoli-Leydig Cell Tumor in a 38-Year-Old Woman: A Case Report, Retrospective Review, and Review of Current Literature. ( 28316852 )
2017
18
An inguinal hernia with cryptorchidism with a Leydig cell tumor in an elderly man: A case report. ( 28171846 )
2017
19
Leydig cell tumor of the testis, presenting with azoospermia. ( 29259494 )
2017
20
DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. ( 28654427 )
2017
21
A Case Report: Ovarian Sertoli-Leydig Cell Tumor With Hyperestrogenism and Endometrial Hyperplasia in a Postmenopausal Woman. ( 28469526 )
2017
22
Sertoli-Leydig cell tumor of the ovary masquerading as a mucinous adenocarcinoma: a frozen section pitfall. ( 29081925 )
2017
23
Incidental Leydig Cell Tumor in Patient with Hormone Resistant Prostate Cancer. ( 28443242 )
2017
24
DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects. ( 27664536 )
2017
25
DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. ( 29037807 )
2017
26
Sertoli-Leydig Cell Tumor with Concurrent Rhabdomyosarcoma: Three Case Reports and a Review of the Literature. ( 28751916 )
2017
27
The co-occurrence of an ovarian Sertoli-Leydig cell tumor with a thyroid carcinoma is highly suggestive of a DICER1 syndrome. ( 26983701 )
2016
28
Recurrent ovarian Sertoli-Leydig cell tumor in a child with Peutz-Jeghers syndrome. ( 28101370 )
2016
29
Sertoli-Leydig cell tumor of the ovary: A diagnostic dilemma. ( 26937481 )
2016
30
Recurrent Sertoli-Leydig cell tumor of ovary in 8-year-old girl. ( 27334531 )
2016
31
Leydig cell tumor found incidentally during microscopic testicular sperm extraction in patient with mosaic Klinefelter syndrome: case report. ( 27523297 )
2016
32
A Rare Case of Intra-Endometrial Leiomyoma of Uterus Simulating Degenerated Submucosal Leiomyoma Accompanied by a Large Sertoli-Leydig Cell Tumor. ( 26847310 )
2016
33
Fertility-sparing management and obstetric outcomes in a 20-year-old patient with a Sertoli-Leydig cell tumor of the ovary: A case report and review of the literature. ( 27446397 )
2016
34
Leydig cell tumor of the testis with azoospermia and elevated delta4 androstenedione: case report. ( 27833751 )
2016
35
Ovarian Sertoli-Leydig cell tumor with heterologous elements containing an unusual type of alpha-fetoprotein-producing cells. ( 27126717 )
2016
36
Sertoli - Leydig cell tumor with retiform areas and overgrowth of rhabdomyosarcomatous elements: case report and literature review. ( 27473538 )
2016
37
Large moderately-differentiated ovarian Sertoli-Leydig cell tumor in a 13-year-old female: A case report. ( 26893701 )
2016
38
Atypical Leydig Cell Tumor in Children: Report of 2 Cases. ( 27940757 )
2016
39
Metastasized Leydig cell tumor in a dog. ( 26753337 )
2015
40
Alopecia and Hirsutism in a Postmenopausal Woman as the Presenting Complaint of Ovarian Hilus (Leydig) Cell Tumor. ( 25910403 )
2015
41
Testicular Leydig Cell Tumor with Metachronous Lesions: Outcomes after Metastasis Resection and Cryoablation. ( 26525589 )
2015
42
Leydig cell tumor in a patient with 49,XXXXY karyotype: a review of literature. ( 26160035 )
2015
43
Leydig cell tumor incidentally detected by fused FDG-PET/MRI. ( 25636443 )
2015
44
Ovarian Sertoli-Leydig Cell Tumor with Predominant Heterologous Mucinous Differentiation and Foci of Hepatocytic Differentiation: Case Report and Review of The Literature. ( 26116602 )
2015
45
The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors. ( 26408257 )
2015
46
Leydig cell tumor with lung metastasis diagnosed by lung biopsy. ( 26722493 )
2015
47
True Precocious Puberty Following Treatment of a Leydig Cell Tumor: Two Case Reports and Literature Review. ( 26579503 )
2015
48
Cervical embryonal rhabdomyosarcoma and ovarian Sertoli-Leydig cell tumor with congenital absence of unilateral ovary. ( 26458643 )
2015
49
Leydig cell tumor of testis with indeterminate features. ( 26960466 )
2015
50
Ovarian Sertoli-Leydig cell tumor with heterologous elements of gastrointestinal type associated with elevated serum alpha-fetoprotein level: an unusual case and literature review. ( 25926909 )
2014
Sources

Variations for Leydig Cell Tumor

About this section
Sources

Expression for Leydig Cell Tumor

About this section
Search GEO for disease gene expression data for Leydig Cell Tumor.
Sources

Pathways for Leydig Cell Tumor

About this section

Pathways related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
DAG and IP3 signaling 66
Show member pathways
 12.69 CYP11A1 LHCGR NR5A1 STAR
2
Aldosterone synthesis and secretion 37
Show member pathways
 12.58 CYP11A1 CYP17A1 CYP21A2 NR5A1 STAR
3
Glucose / Energy Metabolism 4
12.16 CYP11A1 CYP17A1 CYP19A1 STAR
4
G alpha (s) signalling events 66
11.77 INSL3 LHCGR PTHLH
5
Corticotropin-releasing hormone signaling pathway 1
11.55 CYP11A1 CYP21A2 STAR
6
Metabolism of steroid hormones 66
Show member pathways
 11.3 CYP11A1 CYP17A1 CYP19A1 CYP21A2 STAR
7
Steroid hormone biosynthesis 37
Show member pathways
 11.27 CYP11A1 CYP17A1 CYP19A1 CYP21A2
8
Androstenedione and testosterone biosynthesis and metabolism p.1 22
Show member pathways
 11.23 CYP17A1 CYP19A1
9
Ovarian Infertility Genes 1
10.94 CYP19A1 LHCGR NR5A1
10
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.78 CYP17A1 CYP21A2
11
Ovarian steroidogenesis 37
10.71 CYP11A1 CYP17A1 CYP19A1 LHCGR STAR
Sources

GO Terms for Leydig Cell Tumor

About this section

Biological processes related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.86 CYP11A1 CYP17A1 CYP19A1 CYP21A2
2 cell-cell signaling GO:0007267 9.74 INSL3 NR5A1 PTHLH
3 steroid metabolic process GO:0008202 9.7 CYP11A1 CYP17A1 CYP21A2
4 male gonad development GO:0008584 9.65 LHCGR NR5A1 STAR
5 hormone-mediated signaling pathway GO:0009755 9.55 LHCGR NR5A1
6 uterus development GO:0060065 9.54 CYP19A1 LHCGR
7 estrogen biosynthetic process GO:0006703 9.51 CYP19A1 STAR
8 C21-steroid hormone biosynthetic process GO:0006700 9.49 CYP11A1 STAR
9 progesterone metabolic process GO:0042448 9.46 AFP CYP17A1
10 regulation of steroid biosynthetic process GO:0050810 9.43 NR5A1 STAR
11 female gonad development GO:0008585 9.43 CYP19A1 LHCGR NR5A1
12 cellular response to gonadotropin stimulus GO:0071371 9.4 LHCGR STAR
13 testosterone biosynthetic process GO:0061370 9.37 CYP19A1 STAR
14 glucocorticoid biosynthetic process GO:0006704 9.33 CYP11A1 CYP17A1 CYP21A2
15 cellular response to luteinizing hormone stimulus GO:0071373 9.32 LHCGR STAR
16 sterol metabolic process GO:0016125 9.26 CYP11A1 CYP17A1 CYP19A1 CYP21A2
17 steroid biosynthetic process GO:0006694 9.02 CYP11A1 CYP17A1 CYP19A1 CYP21A2 STAR

Molecular functions related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.58 CYP21A2 NR5A1 STAR
2 oxidoreductase activity GO:0016491 9.56 CYP11A1 CYP17A1 CYP19A1 CYP21A2
3 iron ion binding GO:0005506 9.46 CYP11A1 CYP17A1 CYP19A1 CYP21A2
4 oxygen binding GO:0019825 9.37 CYP17A1 CYP19A1
5 steroid hydroxylase activity GO:0008395 9.32 CYP19A1 CYP21A2
6 heme binding GO:0020037 9.26 CYP11A1 CYP17A1 CYP19A1 CYP21A2
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 8.92 CYP11A1 CYP17A1 CYP19A1 CYP21A2
Sources

Sources for Leydig Cell Tumor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....